These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2 files

A Comperehensive Drug Repurposing Study for Covid19 Treatment: Novel Putative DHODH Inhibitors Show Association to Serotonin-Dopamine Receptors

submitted on 01.08.2020, 19:24 and posted on 03.08.2020, 11:16 by Burak Berber, Osman Doluca
Here we discuss the potential of targeting Dihydroorotate dehydrogenase enzyme to help treat Covid 19. Next, we present a very large scale of docking analysis using 7900 drug candidates and 20 Dihydroorotate dehydrogenase structures. Our findings not only identify 28-FDA approved candidate molecules, but also show common characteristics among the candidates, especially their association with serotonin-dopamine receptors. In continuation, we discuss the existing clinical trials for Covid 19 treatment of some of the drug candidates we have identified, supporting that the rest are good candidates.


Email Address of Submitting Author


Izmir University of Economics



ORCID For Submitting Author


Declaration of Conflict of Interest

no conflic of interest